Parana

Migraines cause severe throbbing or pulsating headaches, often on one side of the head, and are linked with nausea and sensitivity to light and sound. This study evaluates Corabotase IPN10200, a medication designed to prevent episodic and chronic migraines by blocking the release of chemicals that cause pain. The research aims to assess the safety, optimal dosing, and effectiveness of Corabotase injections into head and neck muscles. The trial has three periods an initial screening to confirm participant eligibility Step 1, where two doses of Corabotase are tested sequentially in separate cohorts against placebo, with injections administered into head, face, and neck muscles, and safety monitored for 36 weeks and Step 2, where new participants with episodic or chronic migraine are randomly assigned to receive either Dose A, Dose B, or placebo, with injections given in the same muscle areas and both safety and effectiveness tracked until Week 36. Participants complete a daily electronic migraine diary and questionnaires throughout the study, which lasts up to 44 weeks. Researchers monitor adverse events, lab and vital sign changes, facial exams, ECG readings, suicidal behavior, and antibody responses. The main outcome is the reduction in monthly migraine days by Week 12, with ongoing evaluation of headache frequency, medication use, and safety measures through Week 36.

This research evaluates the long-term safety and effects of plozasiran in adults with hypertriglyceridemia HTG and severe hypertriglyceridemia SHTG. Participants must have completed prior related studies and meet specific health criteria, including controlled blood sugar levels HbA1c 10%. The study is designed as an open-label Phase 3 trial to extend understanding of this treatment in these populations. Participants will receive plozasiran injections under the skin approximately every three months for two years. They will continue following a low-fat diet according to local care standards. Some participants may join based on meeting additional criteria from previous studies, ensuring they fit the trials health requirements. During the study, participants will undergo regular assessments including monitoring for treatment-related side effects and changes in blood triglyceride and cholesterol levels. Researchers will track various blood markers and cardiovascular events over 24 months. Safety and response to treatment will be closely observed throughout the trial period.

This research aims to evaluate whether lymphatic surgery improves quality of life better than conservative treatment in patients with chronic breast cancer-related lymphedema BCRL. The study focuses on comparing surgical techniques with the current standard conservative therapy to understand which approach provides better long-term benefits. It is a pragmatic, randomized, international multicenter trial seeking to provide scientific evidence on the effectiveness of surgery over conservative care for this condition. Participants will be randomly assigned to one of two groups. The surgical group may receive lymphovenous anastomosis LVA, vascularized lymph node transfer VLNT, or a combination of both, with some possibly also undergoing liposuction depending on local standards. The conservative group will receive complex physical decongestion therapy CDT, which includes manual lymphatic drainage, compression bandages and garments, physical exercises, and skin care. Both treatments are delivered according to usual care practices, with treatment details and frequency documented. Throughout the study, participants will complete quality of life questionnaires at baseline and 15 months after randomization, with further assessments up to 10 years. Researchers will monitor changes in pain, surgical complications, lymphangitic events, arm volume, frequency of lymphatic drainage, patient burden, and economic impact. The study involves long-term follow-up to evaluate outcomes, safety, and treatment effects, with participation lasting up to 10 years.